Portfolio Analysis in Lyon.

A patent portfolio analysis Lyon in-house teams can act on treats patents as an asset class — something with a carrying cost, a validity risk and a market value, not just a filing at INPI. Lyon is France’s second economic hub and a world capital of vaccines, in vitro diagnostics and industrial chemistry, home to Sanofi Pasteur, bioMérieux, Boehringer Ingelheim and the Vallée de la Chimie. The questions asked of a portfolio here are commercial before they are legal: what is it worth in a deal, where are the gaps a rival could file into, and which SPCs and renewals are quietly draining the budget? PerspireIP answers those questions for the R&D directors and IP counsel running Auvergne-Rhône-Alpes portfolios.

The work is landscape, gap, strength and valuation analysis — not litigation. It is the diligence behind a life-science acquisition, the schedule that lets a Lyonbiopôle spin-out show real IP to a Series B investor, and the renewal and SPC decision that keeps a large chemistry estate from overspending year after year at INPI and the EPO.

Why patent portfolio analysis Lyon teams start with life science and chemistry

Few French cities concentrate patent value in two heavy R&D sectors the way Lyon does. The region is first in the world for human vaccine production through Sanofi Pasteur, a leader in in vitro diagnostics through bioMérieux, and a centre of animal health through Boehringer Ingelheim, all anchored by the Lyonbiopôle cluster and its 200-plus members and a dedicated infectious-diseases biocluster. South of the city, the Vallée de la Chimie runs more than 500 companies and 50,000 jobs — Arkema’s Pierre-Bénite platform and research centre, Solvay, Adisseo and Elkem among them — making chemistry the region’s second patent engine.

That sector mix changes what a review must do. Vaccine and diagnostics families hide their value in supplementary protection certificates and regulatory exclusivity; chemistry estates hide theirs in process, formulation and freedom-to-operate exposure. France’s Crédit d’Impôt Recherche, which reimburses 30% of eligible R&D spend up to €100 million, drives filing volume across both — and volume hides waste. A patent portfolio analysis Lyon owners rely on separates the estate that earns its keep from the estate that merely fills a CIR justification file.

• M&A and private-equity diligence — validity, ownership chain and product coverage of a target’s vaccine, diagnostics or chemistry patents before a bid
• Venture and growth financing — an honest read of whether the IP backs a Lyonbiopôle founder’s story to a Series A or B investor
• CIR and R&D alignment — mapping the estate against the research programmes that generated it
• Board and budget reviews — a periodic strength, gap and cost picture for the direction générale and the general counsel

INPI, the utility certificate and opposition: grading French rights in Lyon

French patents are granted by the Institut national de la propriété industrielle (INPI), which runs a regional délégation for Auvergne-Rhône-Alpes on the quai Perrache in Lyon alongside its Paris headquarters. The value of a French right changed sharply with the PACTE law: before 22 May 2020, INPI examined applications on novelty grounds only and could not refuse a patent for lack of inventive step. For applications filed from that date, INPI conducts full substantive examination, including inventive step, using the same problem-and-solution approach as the EPO. A French patent granted under the new regime is a materially stronger asset than a legacy novelty-only grant.

PACTE also reshaped two tools a Lyon estate uses constantly. It extended the certificat d’utilité (utility certificate) from six to ten years and made it convertible into a full patent — a fast, cheaper right well suited to short-cycle chemistry and device inventions, though enforcing one still requires an INPI search report first. And it created an administrative opposition procedure at INPI, live since 1 April 2020, letting a third party challenge a granted French patent without going to court.

Both cut two ways for a portfolio: your own French patents can now be attacked at the office, and you can use opposition to weaken a competitor’s estate cheaply. A strength review has to grade each significant French asset for its filing date — pre- or post-PACTE — its exposure to opposition, and whether a utility certificate should be kept, converted or allowed to lapse.

SPCs and the biotech patent cliff a Lyon portfolio must manage

For a vaccine, pharmaceutical or animal-health estate, the single most valuable line in the portfolio is often not the patent but the supplementary protection certificate (SPC) that extends it. An SPC offsets the years lost to clinical trials and marketing authorisation, adding up to five years of protection after the basic patent expires, with a further six-month paediatric extension where a Paediatric Investigation Plan applies. In France the certificate is a national right filed at INPI, and the deadline is strict: within six months of the first French marketing authorisation, or of patent grant if that comes later.

For Lyon’s Sanofi Pasteur, bioMérieux and Boehringer Ingelheim ecosystem, and the biotechs orbiting them, SPC hygiene is portfolio hygiene. A missed filing window, a wrongly chosen basic patent, or an SPC that does not actually cover the marketed product can move a blockbuster’s exclusivity cliff by years and change a deal’s value overnight. We map every SPC and pending SPC in the estate against its basic patent, its marketing authorisation and its true expiry — the calendar generics counsel will be watching.

• SPC term mapping — real expiry per product across France and the EPO validation states, not the nominal patent date
• Basic-patent selection — whether the SPC rests on the strongest available patent in the family
• Paediatric extension eligibility — the extra six months where a PIP has been completed
• Cliff and lifecycle planning — when exclusivity ends and where second-medical-use or formulation filings can extend it

Where Lyon patent disputes land: Paris, not Lyon

Portfolio risk is partly forum risk, and in France the forum is singular — and it is not in Lyon. The Tribunal judiciaire de Paris holds exclusive national jurisdiction over French patents, so every infringement, nullity and ownership dispute involving a Lyon company is heard by its specialised intellectual-property chambers in Paris, with no venue anywhere else in the country. Appeals go to the Cour d’appel de Paris and then, on points of law, to the Cour de cassation. First-instance judgments typically arrive within about eighteen months, giving the system a rhythm a portfolio owner can plan around.

That concentration is an advantage for portfolio grading. A single court and appeal court mean one coherent body of case law on claim scope, inventive step and infringement, so a Lyon estate can be scored against consistent precedent rather than a patchwork of regional practice. It also means the same specialist judges see the leading chemistry and life-science patentees again and again.

France’s evidence tool, the saisie-contrefaçon (infringement seizure), is authorised by the President of the Paris court and can be executed at a factory or laboratory anywhere on French territory — including in the Vallée de la Chimie. That is a powerful reason to know, before any dispute, which of your patents are strong enough to anchor an assertion and which a defendant would attack on validity. We flag those exposed assets so the portfolio can be strengthened or pruned in advance rather than under litigation pressure.

The UPC: why Lyon’s chemistry and life-science patents face Munich and Milan

France is a founding member of the Unified Patent Court (UPC) and hosts the seat of its Central Division in Paris, plus a Paris Local Division for infringement actions. For a Lyon portfolio built on chemistry and biotech, the crucial detail is how the Central Division splits work by technology. The Paris seat hears IPC sections B, D, E, G and H and all SPCs; chemistry and metallurgy (IPC section C) go to the Munich section; and human necessities, including pharmaceuticals and biotech (IPC section A), go to the Milan section. Lyon’s two strongest sectors therefore point at two different central-division cities.

The implication is stark. A competitor seeking to invalidate your vaccine or diagnostics European patents can file a central revocation in Milan; one targeting your Vallée de la Chimie process or formulation patents can file in Munich; and a win there kills the patent across every UPC member state at once. Conversely, an opt-out protects a valuable classical European patent from that single point of failure. Mapping which assets sit in which section’s scope, and which have or have not been opted out, is core portfolio intelligence for a Lyon estate.

• Section A → Milan — vaccines, diagnostics, pharma and animal-health European patents face central revocation in Italy
• Section C → Munich — chemistry, materials and metallurgy patents face central revocation in Germany
• Opt-out mapping — which European patents are opted out of the UPC and which are exposed to pan-European attack
• London Agreement — France requires no translation to validate a European patent, lowering the cost of a broad French footprint

Landscape, gap and freedom-to-operate analysis for a patent portfolio analysis Lyon estate

The offensive side of portfolio work is finding what you do not yet own. A landscape maps the patents held by you and your competitors across a technology area; a gap or white-space analysis then shows where protectable, commercially useful inventions sit unclaimed — the ground your R&D directors should file into before a rival does. For a CIR-funded programme, that map also demonstrates to the tax authority that research spend is producing directed, defensible IP.

For Lyon’s chemistry and life-science companies, freedom-to-operate is the landscape question that keeps counsel awake. A new vaccine platform, a diagnostic assay or a fluoropolymer process can read on dozens of third-party patents; launching without clearing them invites a Paris injunction or a UPC action. We build FTO maps that show which live third-party rights read on a planned product, where they can be designed around, and where a licence or an opposition is the cheaper answer — the same analysis, run defensively.

• Competitive landscape maps — who holds what across your technology space, by assignee, claim scope and filing trend
• Gap and white-space analysis — unclaimed, protectable ground to direct the next filing programme
• Freedom-to-operate studies — third-party patents that read on a vaccine, diagnostic or chemistry launch, and the design-around or licensing routes
• Strength and coverage scoring — how well the estate actually covers the products and the roadmap

How PerspireIP builds a Lyon portfolio analysis you can act on

Every engagement follows the same disciplined path, scaled to whether you are prepping a data room, defending a budget or planning next year’s filings. We inventory the portfolio, verify legal status and ownership at INPI and the EPO, map each asset to products and competitors, grade strength against PACTE-era examination and UPC revocation risk, track every SPC and its true expiry, and price the estate for the transaction or decision that prompted the review.

• Full inventory with legal status, term and renewal timeline for every French and European asset, plus every SPC and utility certificate
• Product-to-patent coverage mapping and a claim-strength score across the estate
• Validity grading against INPI opposition and UPC central-revocation exposure in the Milan and Munich sections, with opt-out status flagged
• Landscape, gap, white-space and freedom-to-operate maps for chemistry and life-science technologies
• Renewal-fee and SPC pruning recommendations tied to the next INPI and EPO annuity windows
• A valuation view for M&A, financing or collateral, delivered as data-room-ready exhibits

We work alongside your in-house IP team, your corporate-development group or your outside counsel as a specialist analysis partner, deliver to your deal or budget calendar, and keep every engagement confidential. Whether you need a one-time diligence study before a Lyonbiopôle or Vallée de la Chimie acquisition, an annual portfolio health check for the board, or an ongoing pruning and landscaping programme, we scale to fit. Send us the applicant name or a patent list and we will scope a patent portfolio analysis Lyon project within one business day.

IP Landscape & Resources in Lyon

Key intellectual-property authorities and venues relevant to Lyon:

• Institut national de la propriété industrielle (INPI) — the French patent office that grants French patents, runs an Auvergne-Rhône-Alpes regional délégation in Lyon, has conducted full substantive examination since the PACTE law, and administers SPCs and the opposition procedure
• European Patent Office (EPO) — grants the European patents that Lyon applicants such as Sanofi Pasteur, bioMérieux, Boehringer Ingelheim and Arkema file and that anchor most Auvergne-Rhône-Alpes portfolios
• Unified Patent Court (UPC) — hosts its Central Division seat in Paris, with the Milan section hearing IPC-A life-science revocations and the Munich section hearing IPC-C chemistry revocations with effect across all UPC member states
• Tribunal judiciaire de Paris — the court with exclusive national jurisdiction over French patents, where every Lyon infringement, nullity and ownership dispute is heard before appeal to the Cour d'appel de Paris

Request a Patent Portfolio Analysis in Lyon

Explore related PerspireIP services: Patent Portfolio Analysis services · IP services in France · patent invalidation · prior art search · patent landscape analysis.

Frequently Asked Questions